Characteristics and outcomes according to IDH mutation status at HSCT. (A) ddPCR-based MRD at HSCT in patients with IDH-mutated (ie, IDH1 R132, IDH2 R140, IDH2 R172) AML. (B) Pre-HSCT MRD VAF according to IDH mutation status. (C) CIR, (D) EFS, and (E) OS of HSCT-consolidated patients with AML according to optimized IDH MRD status (IDH1 R132 or IDH2 R172 MRD-positive n = 5; IDH2 R140 MRD-positive n = 11; IDH MRD-negative n = 28).